Links
From the Los Angeles Times:
4 August 2008
A review of the Opening Night of "The Second Opinion" by Susan Brink.
"There were groans in the audience, knowing nods of the head, a good number of men leaving auditorium seats in a rush to the bathroom, and wives giving a comforting rubs to their spouses' arms at each intimate revelation in the documentary they were watching, "The Second Opinion." Many of these men, guests invited by a fledgling group trying to get the word out that they think the standard screening test for prostate cancer is a bad idea, had more than a casual interest in prostate cancer. They've lived through its impossible choices and the often mutilating results of its treatment. Some of them were as sad, frustrated and angry as the men on the screen..."
Read the entire article here.
(This Link will take you out of the Cure Prostate Cancer Foundation website, to return click your browser's Back button.)
From The Loop, Newsletter for the National Registry of Microbiologists:
Vol. 25, #2, p. 2, 1999
"Prostate-Specific Antigen: Promises and Pitfalls," an article by Dr. Richard J. Ablin.
"Heightened awareness, brought forth by the introduction and aggressive marketing of initially indiscriminate screening and media attention focused at high profile celebrity cases, has dramatically altered the epidemiology of prostate cancer (PCa) in the United States (US) within the last decade. Consequently, many view early detection and treatment as rational, ethical, economical, effective and necessary, even in the absence of definitive evidence of their accuracy and efficacy.
The principal, if not sole contributors to the rise of PCa to the most commonly diagnosed type of cancer (excluding skin cancer) among men have been the identification of prostate-specific antigen (PSA) and the PSA antigen test."
Read the entire article here.
From the American Journal of Preventive Medicine
Am J Prev Med 2008;34(2):164–170
"Screening for Prostate Cancer in U.S. Men, ACPM Position Statement on Preventive Practice" by Lionel S. Lim, MD, MPH, FACP, Kevin Sherin, MD, MPH, FACPM, and the ACPM Prevention Practice Committee
"Prostate cancer is the leading cancer in U.S. men, and the third leading cause of cancer deaths. Principal screening tests for detection of asymptomatic prostate cancer include digital rectal examination (DRE) and measurement of the serum tumor marker, prostate-specific antigen (PSA). There are risks and benefits associated with prostate cancer screening. Randomized controlled trials of screening by DRE and PSA are limited to two previously published studies. Two other large-scale randomized controlled trials are currently in progress. Presently, The American College of Preventive Medicine concludes that there is insufficient evidence to recommend routine population screening with DRE or PSA..."
Read the entire article here.
(This Link will take you out of the Cure Prostate Cancer Foundation website, to return click your browser's Back button.)